

Ciaran M Lee

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2772951/ciaran-m-lee-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57 papers	2,694 citations	26 h-index	51 g-index
63 ext. papers	3,628 ext. citations	12 avg, IF	5.33 L-index

#	Paper	IF	Citations
57	Identification and Validation of CRISPR/Cas9 Off-Target Activity in Hematopoietic Stem and Progenitor Cells.. <i>Methods in Molecular Biology</i> , 2022 , 2429, 281-306	1.4	
56	genome editing at the albumin locus to treat methylmalonic acidemia.. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021 , 23, 619-632	6.4	0
55	Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. <i>Molecular Therapy</i> , 2021 ,	11.7	7
54	Development of β globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	12
53	Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing β cell-depleted haploidentical hematopoietic stem cell transplantation. <i>Haematologica</i> , 2021 , 106, 847-858	6.6	18
52	Tools for experimental and computational analyses of off-target editing by programmable nucleases. <i>Nature Protocols</i> , 2021 , 16, 10-26	18.8	12
51	TNF- β synergises with IFN- γ to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells. <i>Cell Death and Disease</i> , 2021 , 12, 864	9.8	6
50	The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells. <i>Nature Communications</i> , 2021 , 12, 472	17.4	7
49	CRISPR-based gene editing enables gene repair in IPEX patient cells. <i>Science Advances</i> , 2020 , 6, eaaz0571	14.3	38
48	Fine-mapping within eQTL credible intervals by expression CROP-seq. <i>Biology Methods and Protocols</i> , 2020 , 5, bpaa008	2.4	6
47	Pitfalls in Single Clone CRISPR-Cas9 Mutagenesis to Fine-map Regulatory Intervals. <i>Genes</i> , 2020 , 11,	4.2	2
46	Site-Specific Post-translational Surface Modification of Adeno-Associated Virus Vectors Using Leucine Zippers. <i>ACS Synthetic Biology</i> , 2020 , 9, 461-467	5.7	2
45	Modulation of inhibitory signals in CAR T cells leads to improved activity against glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3031-3031	2.2	
44	High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia. <i>Cell Stem Cell</i> , 2020 , 26, 161-171.e4	18	50
43	Metabolic engineering generates a transgene-free safety switch for cell therapy. <i>Nature Biotechnology</i> , 2020 , 38, 1441-1450	44.5	12
42	AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9. <i>Molecular Therapy</i> , 2020 , 28, 1432-1441	11.7	72
41	Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. <i>Nature Communications</i> , 2019 , 10, 4045	17.4	44

40	Engineered materials for in vivo delivery of genome-editing machinery. <i>Nature Reviews Materials</i> , 2019 , 4, 726-737	73.3	73
39	Highly efficient editing of the β -globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. <i>Nucleic Acids Research</i> , 2019 , 47, 7955-7972	20.1	67
38	Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung. <i>Nature Communications</i> , 2019 , 10, 2131	17.4	20
37	Gene correction for SCID-X1 in long-term hematopoietic stem cells. <i>Nature Communications</i> , 2019 , 10, 1634	17.4	77
36	Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	59
35	Spatial control of in vivo CRISPR-Cas9 genome editing via nanomagnets. <i>Nature Biomedical Engineering</i> , 2019 , 3, 126-136	19	65
34	Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements. <i>Molecular Therapy</i> , 2019 , 27, 137-150	11.7	58
33	A Self-Deleting AAV-CRISPR System for Genome Editing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019 , 12, 111-122	6.4	62
32	Examination of CRISPR/Cas9 design tools and the effect of target site accessibility on Cas9 activity. <i>Experimental Physiology</i> , 2018 , 103, 456-460	2.4	14
31	Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 1997-2006	9.4	41
30	A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. <i>Nature Medicine</i> , 2018 , 24, 1216-1224	50.5	344
29	Sickle Human Umbilical Cord Derived Erythroid Progenitor Cells (S-HUDEP2): An Ideal in-Vitro System for Screening Anti-Sickling Compounds for Sickle Cell Disease. <i>Blood</i> , 2018 , 132, 3675-3675	2.2	
28	Engineered Human Umbilical Cord Derived Erythroid Progenitor Cells (HUDEP2) with Sickle or β^0 -Thalassemia Mutation: An in-Vitro System for Testing Pharmacological Induction of Fetal Hemoglobin. <i>Blood</i> , 2018 , 132, 3478-3478	2.2	0
27	Persistence of CRISPR/Cas9-Edited Hematopoietic Stem and Progenitor Cells and Reactivation of Fetal Hemoglobin in Nonhuman Primates. <i>Blood</i> , 2018 , 132, 806-806	2.2	
26	Highly Efficient Editing of the Beta-Globin Gene in Patient Derived Hematopoietic Stem and Progenitor Cells to Treat Sickle Cell Disease. <i>Blood</i> , 2018 , 132, 2192-2192	2.2	0
25	In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation Research</i> , 2018 , 123, 953-963	15.7	29
24	Genome editing for inborn errors of metabolism: advancing towards the clinic. <i>BMC Medicine</i> , 2017 , 15, 43	11.4	30
23	CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery. <i>Chemical Reviews</i> , 2017 , 117, 9874-9906	68.1	287

22	CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. <i>Blood</i> , 2017 , 130, 285-296	2.2	183
21	Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. <i>Scientific Reports</i> , 2017 , 7, 44624	4.9	54
20	Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells. <i>Methods in Molecular Biology</i> , 2017 , 1498, 3-21	1.4	5
19	Efficient CRISPR/Cas9-Mediated Genome Editing Using a Chimeric Single-Guide RNA Molecule. <i>Frontiers in Plant Science</i> , 2017 , 8, 1441	6.2	72
18	Analysis of gene repair tracts from Cas9/gRNA double-stranded breaks in the human CFTR gene. <i>Scientific Reports</i> , 2016 , 6, 32230	4.9	21
17	Treating hemoglobinopathies using gene-correction approaches: promises and challenges. <i>Human Genetics</i> , 2016 , 135, 993-1010	6.3	12
16	The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells. <i>Molecular Therapy</i> , 2016 , 24, 645-54	11.7	150
15	Streptococcus thermophilus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome. <i>Molecular Therapy</i> , 2016 , 24, 636-44	11.7	148
14	A Burden of Rare Variants Associated with Extremes of Gene Expression in Human Peripheral Blood. <i>American Journal of Human Genetics</i> , 2016 , 98, 299-309	11	61
13	Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing. <i>Molecular Therapy</i> , 2016 , 24, 475-87	11.7	87
12	Therapeutic Crispr/Cas9 Genome Editing for Treating Sickle Cell Disease. <i>Blood</i> , 2016 , 128, 4703-4703	2.2	7
11	Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β -Thalassemia. <i>Blood</i> , 2016 , 128, 4708-4708	2.2	2
10	Controlled delivery of β globin-targeting TALENs and CRISPR/Cas9 into mammalian cells for genome editing using microinjection. <i>Scientific Reports</i> , 2015 , 5, 16031	4.9	14
9	331. Development of Neisseria meningitidis CRISPR/Cas9 Systems for Efficient and Specific Genome Editing. <i>Molecular Therapy</i> , 2015 , 23, S132-S133	11.7	4
8	Gene Editing with Crispr-Cas9 for Treating Beta-Hemoglobinopathies. <i>Blood</i> , 2015 , 126, 3376-3376	2.2	2
7	Efficient FdCas9 Synthetic Endonuclease with Improved Specificity for Precise Genome Engineering. <i>PLoS ONE</i> , 2015 , 10, e0133373	3.7	42
6	COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. <i>Molecular Therapy - Nucleic Acids</i> , 2014 , 3, e214	10.7	219
5	Correction of the Δ 508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair. <i>BioResearch Open Access</i> , 2012 , 1, 99-108	2.4	64

4	TRACE-Seq Reveals Clonal Reconstitution Dynamics of Gene Targeted Human Hematopoietic Stem Cells	1
3	Gene Correction for SCID-X1 in Long-Term Hematopoietic Stem Cells	1
2	Highly Efficient Repair of the Δ 508 Mutation in Airway Stem Cells of Cystic Fibrosis Patients with Functional Rescue of the Differentiated Epithelia	3
1	Targeted replacement of full-length CFTR in human airway stem cells by CRISPR/Cas9 for pan-mutation correction in the endogenous locus	2